ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,413.70
0.45%
S&P 500
5,307.01
-0.27%
Dow Jones
39,671.04
-0.51%
US Dollar vs Yen
156.7365
0.02%
Brent Oil
81.275
-0.31%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Edgewise Therapeutics Inc (EWTX)

  7. Edgewise Therapeutics Inc (EWTX) ニュース

EWTX

Edgewise Therapeutics (EWTX)

Edgewise Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:EWTX
日付受信時刻ニュースソース見出しコード企業名
2024/05/1022 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/1022 : 07Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/1021 : 00Business WireEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0922 : 21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0921 : 06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0921 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0921 : 00Business WireEdgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0722 : 16Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0722 : 14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0721 : 00Business WireEdgewise Therapeutics Appoints Arlene Morris to its Board of DirectorsNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0621 : 00Business WireEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)NASDAQ:EWTXEdgewise Therapeutics Inc
2024/04/2321 : 00Business WireEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesNASDAQ:EWTXEdgewise Therapeutics Inc
2024/04/1605 : 05Business WireEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)NASDAQ:EWTXEdgewise Therapeutics Inc
2024/03/2821 : 00Business WireEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionNASDAQ:EWTXEdgewise Therapeutics Inc
2024/03/2721 : 00Business WireEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
2024/03/0522 : 00Business WireEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2822 : 00Business WireEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222 : 07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222 : 07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222 : 00Business WireEdgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/1422 : 43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/1322 : 00Business WireEdgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/1007 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/0806 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/2006 : 54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1922 : 44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1922 : 37Business WireEdgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common StockNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1920 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1920 : 04Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:EWTXEdgewise Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:EWTX

最近閲覧した銘柄

AMEX
XLV
Health Care Select Sector
FX
USDGBP
US Dollar vs Sterling
NASDAQ
MSFT
Microsoft
USOTC
ADDYY
Adidas (QX)
USOTC
RHHBY
Roche (QX)
FX
USDEUR
US Dollar vs Euro
NYSE
NKE
Nike
USI
USTECH100
US Tech 100
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
AMEX
XLE
Energy Select Sector SPDR
COIN
BTCUSD
Bitcoin
NASDAQ
AMZN
Amazon.com
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US500
US 500
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有